{
    "brief_title": "Second Line Breast Cancer Trial",
    "phase": "Phase 3",
    "drugs": "['Fulvestrant', 'Anastrozole', 'Fulvestrant']",
    "drugs_list": [
        "Fulvestrant",
        "Anastrozole",
        "Fulvestrant"
    ],
    "diseases": "['Advanced Breast Cancer']",
    "diseases_list": [
        "Advanced Breast Cancer"
    ],
    "enrollment": "588.0",
    "inclusion_criteria": "inclusion criteria: \n\n postmenopausal women with confirmation of breast cancer \n\n objective evidence of recurrence or progression of breast cancer no more than 1 prior hormonal therapy for breast cancer \n\n ",
    "exclusion_criteria": ": \n\n presence of life-threatening metastatic visceral disease \n\n previous treatment with FASLODEX, ARIMIDEX or any aromatase inhibitor for breast cancer \n\n more than 1 prior endocrine medical treatment for advanced breast cancer .",
    "brief_summary": "The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.",
    "NCT_ID": "NCT00635713"
}